LONDON (ShareCast) - (Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.
The AIM-traded firm said the award underlined the "strong clinical development and commercial progress" it had made over the last 12 months.

That included positive data from the ongoing phase 1 and 2a clinical trial in retinitis pigmentosa, and the signing of an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development Company for the development, manufacture and commercialisation of ReNeuron's CTX and hRPC cell therapy programmes in the People's Republic of China.

"We are delighted to have been awarded the Breakthrough of the Year award at the 2019 European Mediscience Awards," said ReNeuron chief executive officer Olav Hellebø.

"We are greatly encouraged by the progress we have made with our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability over the past year and look forward to continuing to advance our clinical and business development activities in the months ahead."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE